Many patients with rheumatic diseases complain of insomnia. Its management has been the subject of earlier studies.1-3 Pain,1 3 than the controls. The only significant difference in the sleep of controls on the first and second baseline nights was an increased number of awakenings on the second baseline night (p<0-05). In the osteoarthritic patients there were no significant differences between the two baseline nights. Discussion
With the exception of psychotropic drugs, which were discontinued, osteoarthritic patients continued with their usual drug regimen throughout the course of the study. Such medication was needed on ethical grounds as most of these patients had severe pain and discomfort. It also enabled a realistic evaluation of sleep in osteoarthritic patients, most of whom would normally be receiving anti-inflammatory or analgesic medication, or both. The purpose of the baseline night 1 versus baseline night 2 comparison within each of the two groups was to check that sleep was similar on both baseline nights. Differences between baseline nights could be due to an incomplete adaptation to the sleep laboratory or marked night to night variation in either group. The only significant difference observed was with the controls, who had an increased number of awakenings on the second baseline night. This finding is the opposite of that which might be expected if the controls were incompletely adapted to the sleep laboratory, because adaptation and therefore sleep would improve with successive nights.
The average of the baseline nights was considered the most representative of normal sleep and was used in the comparison of sleep in osteoarthritic patients and controls. The increased percentage stage 1 sleep and reduced percentage stage 2 sleep observed in the osteoarthritic patients is indicative of sleep disturbance. Stage 1 sleep, or drowsiness, is considered so close to wakefulness that many researchers (including the authors) use stage 2 rather than stage 1 as an indication of sleep onset.14 Although the patients continued with their routine medication, significant differences were observed between the two groups. If the osteoarthritic patients had been deprived of their analgesics and anti-inflammatory medication it is possible that the degree of sleep disturbance would have been much worse. The previous comparison by Moldofsky et al of EEG sleep variables in fibrositic patients and normals also showed a difference in stage 1 sleep, the fibrositic group spending about twice as long in this stage.9
Differences in EEG sleep variables have been reported in a number of chronic diseases. Patients with angina showed significantly longer sleep latencies, reduced stages 3 and 4, and less efficient sleep than healthy controls.6 Asthmatic patients also showed differences, including significantly less total sleep time and stage 4 sleep than normal controls.5
These findings suggest that sleep disturbance represents a non-specific change resulting from many predisposing factors. In osteoarthritis the stimulus for its occurrence might arise from the joints or muscles.
This demonstration of an objective difference in the sleep of osteoarthritic patients lends weight to the consideration of sleep disturbance as an indication for arthroplasty or other surgical intervention. Studies are in progress to determine whether surgery improves sleep in osteoarthritis and whether it is the use of analgesics, anti-inflammatory agents, hypnotic drugs, or combinations of these that best improve sleep. 
